PROPELLING PRECISION MEDICINE FORWARD TO IMPROVE HEALTH FOR ALL

As a global Contract Research Organization Laboratory (CRO) to the biopharmaceutical industry, CellCarta provides access to a broad offering of biomarker platforms and services.  We partner with you to address the most complex scientific testing needs, delivering customized biomarker testing solutions to further the limitless potential of precision medicine.

CellCarta, which is under the private ownership of Arsenal Capital, is the union of scientific pioneers of the CRO industry supporting discovery, translational and clinical research.  At the core of CellCarta is the fusion in 2019 of Caprion Biosciences and HistoGeneX which brought together a unique combination of biomarker expertise focused on immune monitoring, histopathology, proteomics and genomics, including the capabilities of previously acquired Primity Bio and Serametrix.

Leveraging its presence on four continents and through the addition of Clinical Logistics Inc., Mosaic Laboratories and Biogazelle, which further expanded its specimen logistics services and biomarker franchise, CellCarta is uniquely positioned to provide complex and customized clinical biomarker solutions at the global level.

Office Locations

201 President Kennedy Ave., Suite 3900
Montreal, Quebec
CANADA H2X 3Y7